1093 related articles for article (PubMed ID: 18623907)
1. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
2. Serogroup C meningococcal conjugate vaccines: new preparations. Effective from age two months.
Prescrire Int; 2003 Apr; 12(64):43-6. PubMed ID: 12675020
[TBL] [Abstract][Full Text] [Related]
3. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
4. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
5. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
Oster P; Lennon D; O'Hallahan J; Mulholland K; Reid S; Martin D
Vaccine; 2005 Mar; 23(17-18):2191-6. PubMed ID: 15755593
[TBL] [Abstract][Full Text] [Related]
6. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
7. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
Arnold R; Galloway Y; McNicholas A; O'Hallahan J
Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal disease: a review on available vaccines and vaccines in development.
Bröker M; Fantoni S
Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
[TBL] [Abstract][Full Text] [Related]
11. MeNZB vaccine and epidemic control: when do you stop vaccinating?
Loring BJ; Turner N; Petousis-Harris H
Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
[TBL] [Abstract][Full Text] [Related]
12. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
[TBL] [Abstract][Full Text] [Related]
13. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
[TBL] [Abstract][Full Text] [Related]
14. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
[TBL] [Abstract][Full Text] [Related]
15. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.
Kelly C; Arnold R; Galloway Y; O'Hallahan J
Am J Epidemiol; 2007 Oct; 166(7):817-23. PubMed ID: 17615088
[TBL] [Abstract][Full Text] [Related]
18. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
[TBL] [Abstract][Full Text] [Related]
19. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
[TBL] [Abstract][Full Text] [Related]
20. The strategy to control New Zealand's epidemic of group B meningococcal disease.
O'Hallahan J; Lennon D; Oster P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
